Valued at a market cap of $8.9 billion, The Mosaic Company (MOS) is a leading global producer and marketer of concentrated ...

Mosaic Therapeutics has secured the latest pieces in its combination medicine strategy by licensing two clinical stage tumor ...

We have seen 272 institutional investors add shares of MOS stock to their portfolio, and 342 decrease their positions in their most recent quarter. Wall Street ...

The Mosaic Company, through its subsidiaries, produces and markets concentrated phosphate and potash crop nutrients in the United States, Brazil, China, Canada, Paraguay, Argentina, Japan ...

Mosaic Therapeutics, Ltd ('Mosaic') a targeted oncology therapeutics company dedicated to resolving cancer's complexity with ...

The Mosaic Company (MOS) is a stock many investors are watching right now. MOS is currently holding a Zacks Rank of #2 (Buy) and a Value grade of A. The stock has a Forward P/E ratio of 12.14.

Mosaic Co. closed 13.72% short of its 52-week high of $32.29, which the company reached on May 22nd.

Mosaic Therapeutics Ltd, a targeted oncology therapeutics company dedicated to resolving cancer’s complexity with new ...

As part of the deal Astex has acquired a 19% equity stake in Mosaic upfront with a potential for an additional 3% upon reaching clinical milestones. Dr Harren Jhoti Co-founder President and Chief ...

TAMPA, FL / ACCESS Newswire / April 16, 2025 / The Mosaic Company (NYSE:MOS) plans to release first quarter 2025 earnings results on Tuesday, May 6th, after close of trading on the New York Stock ...

Syncona Limited Mosaic Therapeutics in-licences two clinical-stage assets from Astex Pharmaceuticals In-licensing these clinical-stage assets has significantly de-risked and accelerated Mosaic’s ...